Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 14, 2014 - Issue 8
Submit an article Journal homepage
500
Views
5
CrossRef citations to date
0
Altmetric
Drug Evaluations

Obinutuzumab for B-cell malignancies

Carolyn J OwenUniversity of Calgary, Tom Baker Cancer Centre, Division of Hematology and Hematological Malignancies, 603 South Tower, Foothills Medical Centre, 1403-29th St NW, Calgary, Alberta, T2N 2T9, [email protected]
, MD MDres(UK) FRCPC &
Douglas A StewartUniversity of Calgary, Tom Baker Cancer Centre, Division of Hematology and Hematological Malignancies, 603 South Tower, Foothills Medical Centre, 1403-29th St NW, Calgary, Alberta, T2N 2T9, [email protected]
, MD FRCPC
Pages 1197-1205 | Published online: 23 May 2014

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Sonia Cerquozzi & Carolyn Owen. (2015) Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia. Biologics: Targets and Therapy 9, pages 13-22.
Read now
Stefano Molica. (2015) Progress in the treatment of elderly/unfit chronic lymphocytic leukemia patients: results of the German CLL-11 trial. Expert Review of Anticancer Therapy 15:1, pages 9-15.
Read now

Articles from other publishers (3)

Burak Deveci & Rabin Saba. (2021) Prolonged viral positivity induced recurrent coronavirus disease 2019 (COVID-19) pneumonia in patients receiving anti-CD20 monoclonal antibody treatment. Medicine 100:52, pages e28470.
Crossref
Patrick J. Engelberts, Ida H. Hiemstra, Bart de Jong, Danita H. Schuurhuis, Joyce Meesters, Irati Beltran Hernandez, Simone C. Oostindie, Joost Neijssen, Edward N. van den Brink, G. Jean Horbach, Sandra Verploegen, Aran F. Labrijn, Theodora Salcedo, Janine Schuurman, Paul W.H.I Parren & Esther C.W. Breij. (2020) DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine 52, pages 102625.
Crossref
Daniel S. Pereira, Claudia I. Guevara, Liqing Jin, Nathan Mbong, Alla Verlinsky, Ssucheng J. Hsu, Hector Aviña, Sher Karki, Joseph D. Abad, Peng Yang, Sung-Ju Moon, Faisal Malik, Michael Y. Choi, Zili An, Kendall Morrison, Pia M. Challita-Eid, Fernando Doñate, Ingrid B.J. Joseph, Thomas J. Kipps, John E. Dick & David R. Stover. (2015) AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody–Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML. Molecular Cancer Therapeutics 14:7, pages 1650-1660.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.